Scientific Data: A study found that Byetta was associated with more frequent nausea compared to other GLP-1 medications
In the LEADER trial, over 9,340 patients with type 2 diabetes and high cardiovascular disease risk underwent randomization to liraglutide or placebo and were followed for a median of 3.8 years resulting in a 13% risk reduction in a combined endpoint of death from cardiovascular cause, nonfatal myocardial infarction, or nonfatal stroke [46]
Shi K, Zhang G, Fu H, Li XM, Gao Y, Shi R, Xu HY, Li Y, Guo YK, Yang ZG
These cardiovascular benefits likely require sustained, adequate receptor activation across all three targets, raising further questions about whether microdosing preserves them
Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes
If a once weekly injection is missed, it can usually be administered within four days